Novo Nordisk reprimanded for allegedly failing to disclose payments
The manufacturer of the weight loss jab Wegovy has been reprimanded for allegedly failing to disclose or accurately report payments to healthcare and patient organisations.
Novo Nordisk breached clauses under the Association of the British Pharmaceutical Industry (ABPI) code of practice, according to the Prescription Medicines Code Of Practice Authority (PMCPA).
The company said it is taking the issue 'extremely seriously' and 'is dedicated to working transparently and ethically'.
The complaint was made by three individuals, who were colleagues at two separate universities, regarding the alleged failure to report payments to two healthcare organisations.
Following an 'in-depth investigation', the complainants claimed Novo Nordisk allegedly failed to report, inaccurately reported, and misreported payments to healthcare organisations and patient organisations between 2015 and 2022.
The probe alleged 30 organisations were missed from the company's disclosures and claims Novo Nordisk misreported 65 payments.
The PMCPA said Novo Nordisk accepted breaches of clauses 24.1, 24.4, 24.5, 27.7, 9.1 and 2 of the 2019 code and clauses 28.1, 29.1, 29.2, 31.1, 31.2, 5.1 and 2 of the 2021 code.
These clauses include failing to document and publicly disclose annually certain payments made directly or indirectly to health professionals, other relevant decision-makers and healthcare organisations, failing to make publicly available a list of patient organisations which it supports, and failing to make disclosures annually in respect of each calendar year in the first six months after the end of the calendar year in which the payments were made.
It added that its panel 'decided on balance not to report Novo Nordisk to the code of practice appeal board for it to decide whether the imposition of further sanctions was appropriate'.
It noted that the company 'had been the subject of several cases in relation to the failure to appropriately disclose transfers of value,' adding that 'additional sanctions had been imposed and that Novo Nordisk was already the subject of the audit process at the request of the code of practice appeal board'.
It said the 'matters raised in this case were closely similar to matters already before the appeal board both in terms of the nature of the matters considered and that the amount undisclosed was significant'.
Novo Nordisk has its headquarters in Bagsvaerd in Denmark, and was founded in 1923.
Among its products is semaglutide, sold under the brand names Ozempic and Wegovy, the latter of which has been approved to treat obesity on the NHS.
A Novo Nordisk spokesman said: 'Novo Nordisk is dedicated to working transparently and ethically, taking the reporting of these historical transfers of value extremely seriously.
'In fact, most of the missed disclosures included in this case were already part of our self-reported voluntary admission in November 2023 to the PMCPA.
'For those that were not included in that admission, these have been captured through our improved processes and have been accurately disclosed.
'All transfers of value related to this case were related to legitimate activities, in line with the UK pharmaceutical industry's code of practice.
'We continue to strengthen our compliance framework in the UK and remain committed to adhering to the ABPI code of practice and maintaining the highest possible ethical standards required by the pharmaceutical industry.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Weight-Loss Medications Less Effective for People in the 'Real World,' New Study Finds
A new study analyzed patients who used GLP-1 medications in a real-world setting Researchers found that participants lost less weight compared to use in clinical trials They believe discontinuation rates are due to high out-of-pocket costs, issues with insurance coverage, side effects and supply shortagesWeight-loss medications like Ozempic and Mounjaro are not as effective in a 'real-world' setting, according to a new study. The study — published June 10 in the Obesity Journal — analyzed nearly 8,000 patients who were classified as having severe obesity. Between 2021 and 2023, they were treated with semaglutide or tirzepatide, injectable GLP-1 medications, in a real-world setting. GLP-1 is short for glucagon-like peptide-1 receptor agonists, which work in the brain to impact satiety. Semaglutide is sold under brand names Ozempic and Wegovy, and tirzepatide is sold under brand names Mounjaro and Zepbound. In a follow-up study, which ended in December 2024, researchers grouped patients who discontinued their obesity medications into those who discontinued early (within 3 months) and late (within 3-12 months). Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! They found that more than 20% of patients discontinued their medications early and 32% discontinued their medications late. Additionally, more than 80% of patients were on lower maintenance dosages of their medications. After a year of treatment, the average weight loss was 3.6% for those who discontinued their treatment early, compared to 6.8% for those who discontinued their treatment late. Those who continued treatment lost about 12% of their body weight. During clinical trials for the GLP-1s, patients lost about 15% to 20% of their body weight. 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' Dr. Hamlet Gasoyan, Cleveland Clinic researcher and lead author of the study, said in a statement. The study notes that discontinuation rates during real-world use were higher than those in a clinical trial setting due to high out-of-pocket costs, issues with insurance coverage, side effects and supply shortages. Read the original article on People
Yahoo
4 hours ago
- Yahoo
Baby Boomers' Luck Is Running Out
The Atlantic Daily, a newsletter that guides you through the biggest stories of the day, helps you discover new ideas, and recommends the best in culture. Sign up for it here. At the core of every joke about Baby Boomers lies a seed of jealousy. Unlike younger generations, they have largely been able to walk a straightforward path toward prosperity, security, and power. They were born in an era of unprecedented economic growth and stability. College was affordable, and they graduated in a thriving job market. They were the first generation to reap the full benefits of a golden age of medical innovations: birth control, robotic surgery, the mapping of the human genome, effective cancer treatments, Ozempic. But recent policy changes are poised to make life significantly harder for Baby Boomers. 'If you're in your 60s or 70s, what the Trump administration has done means more insecurity for your assets in your 401(k), more insecurity about sources of long-term care, and, for the first time, insecurity about your Social Security benefits,' Teresa Ghilarducci, a labor economist at the New School, told me. 'It's a triple threat.' After more than half a century of aging into political and economic trends that worked to their benefit, the generation has become particularly vulnerable at exactly the wrong moment in history. Perhaps the biggest threat to Boomers in the second Trump administration is an overhaul of Social Security, which provides benefits to nearly nine out of 10 Americans ages 65 and older. In an emailed statement, Social Security Commissioner Frank Bisignano wrote, 'I am fully committed to upholding President Trump's promise to protect and strengthen Social Security. Beneficiaries can be confident that their benefits are secure.' But in February, DOGE announced plans to cut Social Security staff by about 12 percent and close six of its 10 regional offices; a quarter of the agency's IT staff has quit or been fired. Social Security's long-term outlook was already troubled before Trump, and these drastic reductions make the understaffed agency even less equipped to support those who rely on it. Shutting down field offices means seniors can't get help in person; less staffing means longer wait times when they call and more frequent website crashes. 'When you add hurdles, or cause a slowdown in terms of processing claims, you see losses in terms of benefits,' Monique Morrissey, a senior economist at the Economic Policy Institute, told me. In fact, shutdowns of field offices during the first two years of the coronavirus pandemic corresponded with decreased enrollment in both Social Security and Social Security Disability Insurance, which is available to Americans under 65 who can no longer work for physical or mental reasons. Social Security cuts will most hurt low-income Boomers, who are the likeliest to rely on benefits to cover their whole cost of living. But even those with more financial assets may depend on Social Security as a safety net. 'It's important to understand that many seniors, even upper-income seniors, are just one shock away from falling into poverty,' says Nancy J. Altman, the president of Social Security Works, an organization that advocates for expanding the program. As a whole, seniors have more medical needs and less income than the general population, so they're much more financially vulnerable. If you're comfortably middle-class in your early 60s, at the height of your earning potential, that's no guarantee that you'll remain comfortably middle-class into your 70s. In the next few years, Boomers who face more medical bills as they stop working might find, for the first time in their life, that they can't easily afford them. Middle-income seniors are also likely to feel the impact of a volatile market. 'They tend to have modest investments and fixed incomes rather than equities, so the type of wealth that will erode over a high-inflation period,' Laura D. Quinby, who studies benefits and labor markets at the Center for Retirement Research at Boston College, told me. After Trump announced 10 percent tariffs on all imported goods in April, the three major stock indexes dropped 4 percent or more. They've since recovered, but the erratic market—whipped around by Trump's shifting proclamations about tariffs—scares many middle-class Boomers, who are watching their retirement savings shrink. In the near future, older Americans might find themselves paying more for medical care too. Trump's 'big, beautiful bill,' which has passed in the House but awaits a vote in the Senate, would substantially limit Medicare access for many documented immigrants, including seniors who have paid taxes in the United States for years. The bill would also reduce Medicaid enrollment by about 10.3 million people. Although Medicaid is for people with limited incomes of all ages, it supports many older Americans and pays for more than half of long-term care in the U.S. Most seniors require some sort of nursing home or at-home medical care; one study found that 70 percent of adults who live to 65 will require long-term services and support. [Read: The GOP's new Medicaid denialism ] That support may soon be not only more expensive, but harder to come by. The long-term-care workforce is disproportionately made up of immigrants, so the Trump administration's immigration crackdown is likely to reduce the number of people available to take care of seniors—and increase how much it costs to hire them. 'If you have no money, you'll be on Medicaid in a nursing home, and that's that. But if you're trying to avoid that fate, you're now going to run through your money more quickly and be more vulnerable,' Morrissey said. Seniors with some financial security are more likely to live long enough to contend with the diseases of old age, such as Alzheimer's and dementia. The Trump administration has cut funding for promising research on these diseases. 'Going forward, you'll find less treatments reaching fruition,' Thomas Grabowski, who directs the Memory and Brain Wellness Center at the University of Washington, told me. For now, the UW Memory and Brain Wellness Center, where Grabowski works on therapies for Alzheimer's, has stopped bringing in new participants; as time goes on, he said, they'll have to tighten more. (Kush Desai, a White House spokesperson, told me in an email that the cuts to research funded by the National Institutes of Health are 'better positioning' the agency 'to deliver on medical breakthroughs that actually improve Americans' health and wellbeing.') Changes at the UW Memory and Brain Wellness Center could have dramatic effects on current patients, including Bob Pringle, a 76-year-old who lives in Woodinville, Washington. In April, he started getting infusions of donanemab, an anti-amyloid medication approved by the FDA last year. The drug doesn't cure Alzheimer's; it's designed to slow the disease's progression, though the utility of donanemab and other Alzheimer's drugs remains controversial among experts. Pringle, for one, has found donanemab helpful. 'With the medication, my decline is a gentle slope, rather than a rapid decline,' says Pringle, whose mother died of Alzheimer's and whose sister lives in a memory-care facility. 'You're always hopeful that somebody with a bigger brain than you have is working on a cure, and the medication gives us some time until then,' Bob's wife and caretaker, Tina Pringle, told me. 'But right now, because of the funding cuts, our outlook is grim.' [Read: The NIH's most reckless cuts yet] The unknowability of the future has always been a scary part of getting older. The enormous upheaval that the Trump administration has created will only magnify that uncertainty for Boomers. After a historical arc of good fortune, their golden generation has to contend with bad timing. Younger generations, including my own, shouldn't gloat, though: Cuts to Social Security and a halt to medical research could well worsen the experience of aging for generations to come. Younger Americans will likely grow old under challenging conditions too. Unlike the Boomers, we'll have plenty of time to get used to the idea. Article originally published at The Atlantic
Yahoo
5 hours ago
- Yahoo
Novo Nordisk ramps up obesity fight, advances amycretin to Phase III
Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and who are overweight. Following a positive end-of-Phase II meeting, Novo Nordisk shared that regulatory authorities have approved the therapy to proceed. The company plans to initiate the trial in adults who are overweight or with obesity in Q1 2026. Executive vice president for development at Novo Nordisk, Martin Lange said: 'We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to Phase III. We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the Phase III programme.' In a Phase Ib/IIa study (NCT06064006), amycretin, a glucagon-like peptide-1 (GLP-1) and amylin receptor co-agonist, showed weight-loss outcomes of up to 22% in 36 weeks. This was higher than seen by the company's blockbuster therapy Wegovy (semaglutide), which demonstrated a body weight change of 14% at week 36 in a Phase II study. The Phase Ia/IIb study investigated three doses of once-weekly subcutaneous amycretin in 125 patients who are overweight or with obesity. The primary endpoint was treatment-emergent adverse events (TEAEs), with Novo Nordisk reporting that the most common events were gastrointestinal, and the majority were mild to moderate in severity. If successful in a Phase III trial, GlobalData anticipates that amycretin will receive approval for adults with overweight or obesity in Q4 2030 in the US, followed by approval in the EU in Q1 2031. GlobalData is the parent company of Clinical Trials Arena. Novo Nordisk has signed a $812m partnership with Deep Apple Therapeutics to access novel compounds, not GLP-1RAs, for obesity and other diseases. As well as this, the company has also listed two new studies for CagriSema, another candidate in its pipeline. The company recently announced underwhelming data from a Phase III trial, which, while meeting its primary endpoint, fell short of the 25% weight loss promise. Following all these updates, Novo Nordisk's share price has now increased, making it the most valuable company in Europe once again. It has a market cap of $359.28bn compared to German software company SAP at $359bn. Novo Nordisk's flagship semaglutide, marketed as Wegovy in weight loss and Ozempic in type 2 diabetes, is forecast to make $49bn in sales in 2030, according to GlobalData. Its main competitor, Eli Lilly's tirzepatide, marketed as Zepbound in weight loss and Mounjaro in type 2 diabetes, is projected to reach sales of $60.8bn. Lilly's drug proved to have higher efficacy than Novo Nordisk's in a head-to-head study between the pair. "Novo Nordisk ramps up obesity fight, advances amycretin to Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
